Fosamax and Osteonecrosis of the Jaw: Understanding the Pathophysiology and Causation
Latest update (2026-05)
FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]
From General Health to Occupational Exposure Context
The legacy of general health and science information has long provided a foundation for public understanding of medication effects and disease processes. Within this broad context, discussions of bone health and pharmaceutical interventions have traditionally focused on therapeutic benefits and broad safety profiles. As scientific communication evolves, there is increasing recognition that certain medications, while effective for their intended purposes, may present specific risks under particular conditions of use. This shift in perspective moves the conversation from general health maintenance toward more targeted considerations of exposure scenarios. In occupational settings, where individuals may have prolonged or repeated contact with pharmaceutical agents during manufacturing, handling, or administration, the potential for adverse outcomes becomes a distinct concern. The transition from a general health framework to one emphasizing occupational exposure requires careful attention to how medication-related risks are contextualized within workplace environments. This pivot acknowledges that the same compounds discussed in patient education materials may pose different challenges when encountered by workers in production or clinical settings. The focus thus narrows from population-level health guidance to the specific circumstances of occupational contact, setting the stage for examining how particular exposures might relate to tissue-level responses without delving into mechanistic pathways.
Bridging to Fosamax and ONJ Pathophysiology
Building on the occupational exposure framework, we now examine Fosamax (alendronate), a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism of action involves inhibiting bone resorption by osteoclasts, which reduces bone turnover. However, this suppression of normal bone remodeling has been linked to a serious adverse effect: osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including FOSAMAX (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The pathophysiology of how Fosamax triggers ONJ is rooted in its pharmacological action on bone metabolism. Bisphosphonates like alendronate accumulate in the skeleton, particularly at sites of high bone turnover. The jawbone, due to its constant mechanical stress from chewing and its high rate of remodeling, is especially susceptible to the effects of these drugs. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Studies using animal models have examined the effects of bisphosphonate (alendronate) on jawbone, including tissue mineral density distribution and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/).
Mechanistic Pathways and Risk Factors
The mechanistic pathway involves several steps. First, Fosamax inhibits osteoclast activity, which reduces the rate of bone resorption and turnover. In the jaw, this suppression can impair the normal healing response to microdamage or dental procedures. Second, the drug's anti-angiogenic properties may reduce blood supply to the jawbone, further compromising tissue viability. Third, the accumulation of bisphosphonate in the bone matrix can lead to local toxicity, affecting osteocytes and other cells. When a dental procedure such as tooth extraction occurs, the bone's inability to remodel and repair properly can result in necrotic bone exposure. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the timeline between exposure and documented harm, the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability suggests that individual patient factors, such as dental health and concurrent medications, play a significant role. Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of FOSAMAX, the percentages of patients with these symptoms were similar in the FOSAMAX and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that ONJ is a rare event that may require additional risk factors to manifest.
Causation Considerations and Clinical Management
Causation-related considerations for affected patients are complex. While Fosamax is associated with ONJ, the condition is multifactorial. The drug labeling advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of use has not been determined, and for patients at low-risk for fracture, drug discontinuation after 3 to 5 years of use is considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The adequacy of warnings regarding Fosamax and ONJ is addressed in the product labeling, which includes a specific section on osteonecrosis of the jaw. The labeling describes the condition, its association with dental procedures, and known risk factors. It also notes that the risk may increase with duration of exposure and that discontinuation may reduce risk for ONJ in patients requiring invasive dental procedures. This information provides healthcare providers and patients with important guidance for risk management. In summary, Fosamax can trigger osteonecrosis of the jaw through its suppression of bone remodeling, particularly in the jawbone, which has unique structural and metabolic characteristics. The pathophysiology involves reduced osteoclast activity, impaired healing, and potential local toxicity. The timeline for onset varies, and the condition is often associated with dental procedures or other risk factors. While the drug labeling includes warnings and risk mitigation strategies, the multifactorial nature of ONJ means that causation in individual cases requires careful evaluation of exposure, risk factors, and clinical presentation.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the mechanism by which Fosamax causes osteonecrosis of the jaw?
Fosamax (alendronate) inhibits osteoclast activity, reducing bone resorption and turnover. In the jawbone, this suppression impairs healing responses to microdamage or dental procedures. Additionally, anti-angiogenic effects may reduce blood supply, and accumulation of the drug in bone matrix can cause local toxicity, leading to necrotic bone exposure. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)
What are the known risk factors for developing ONJ while taking Fosamax?
Risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures). Duration of bisphosphonate exposure may increase risk. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1)
How long after starting Fosamax can ONJ symptoms appear?
Free and confidential. No obligation — an initial records screening only.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.